Health Services Research & Development

• Huang CF, Iio E, Jun DW, Ogawa E, Toyoda H, Hsu YC, Haga H, Iwane S, Enomoto M, Lee DH, Wong G, Liu CH, Tada T, Chuang WL, Cheung R, Hayashi J, Tseng CH, Yasuda S, Tran S, Kam L, Henry L, Jeong JY, Nomura H, Park SH, Nakamuta M, Huang JF, Tai CM, Lo GH, Lee MH, Yang HI, Kao JH, Tamori A, Eguchi Y, Ueno Y, Furusyo N, Tanaka Y, Yu ML, Nguyen MH, REAL-C Investigators. Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. Hepatology international. 2019 Sep 1; 13(5):587-598.
• Uyei J, Taddei TH, Kaplan DE, Chapko M, Stevens ER, Braithwaite RS. Setting ambitious targets for surveillance and treatment rates among patients with hepatitis C related cirrhosis impacts the cost-effectiveness of hepatocellular cancer surveillance and substantially increases life expectancy: A modeling study. PLoS ONE. 2019 Aug 26; 14(8):e0221614.
• Gidwani-Marszowski R, Owens DK, Lo J, Goldhaber-Fiebert JD, Asch SM, Barnett PG. The Costs of Hepatitis C by Liver Disease Stage: Estimates from the Veterans Health Administration. Applied Health Economics and Health Policy. 2019 Aug 1; 17(4):513-521.
• Hanberg JS, Freiberg MS, Goetz MB, Rodriguez-Barradas MC, Gibert C, Oursler KA, Justice AC, Tate JP, VACS Project Team. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Inflammatory Biomarkers in Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), and HIV/HCV Coinfection. Open forum infectious diseases. 2019 Oct 1; 6(10):ofz347.
• Zullig LL, Bhatia HL, Gellad ZF, Eatherly M, Henderson R, Bosworth HB. Adoption of direct-acting antiviral medications for hepatitis C: a retrospective observational study. BMC health services research. 2019 Jul 25; 19(1):521.

» View more Citations

• VA Successfully Implements Interferon-free Treatment for Hepatitis C Virus in Previously Undertreated Patient Populations
  This study examined the adoption of interferon-free treatment for hepatitis C virus (HCV) in VA to learn who received this therapy and whether the limitations of interferon-containing treatments have been overcome, including low rates of use among VA healthcare users who are African American or Hispanic, and among those with HCV-HIV co-infection. Findings showed that with the advent of interferon-...
  
  Date: March 7, 2018
• HCV-Related Complications Increasing among Women Veterans
  This study examined gender-related differences in the incidence and prevalence of cirrhosis, decompensated cirrhosis, and hepatocellular cancer (HCC) between 2000 and 2013. Findings showed that the incidence and prevalence of hepatitis C virus (HCV) complications was higher in men than in women. However, the rate of increase in the incidence rates of cirrhosis and decompensated cirrhosis among HCV...
  
  Date: November 1, 2017
• Direct-Acting Antiviral Agents Reduce Risk of Hepatocellular Cancer among Veterans with Hepatitis C
  This study examined the risk of hepatocellular cancer (HCC) following sustained virological response (SVR) among 22,500 Veterans with hepatitis C virus (HCV) who received directing-acting antivirals (DAA) treatment at any of 129 VA hospitals between January and December 2015. Findings showed that in Veterans treated with DAAs, SVR was associated with a 76% reduction in the risk of developing hepat...
  
  Date: October 1, 2017
• VA Hepatitis C Care and Experiences with the Choice Program
  This study examined perspectives and experiences with the VA Choice Program among Veterans with HCV and their providers at three VAMCs in the New England region. Findings showed that the Choice Program has the potential to increase Veterans’ access to hepatitis C virus (HCV) treatment, but Veterans and VA providers described substantial problems in the initial years of the program. Four main theme...
  
  Date: March 3, 2017
• Engagement in Hepatitis C Virus Care among Homeless and non-Homeless VA Patients
  This study sought to describe engagement in hepatitis C virus (HCV) care among homeless and non-homeless Veterans in the new era of HCV treatment, which includes direct-acting agents (DAAs) with shorter treatment durations, fewer side effects, and higher sustained virologic response (SVR) rates than the older treatment regimens. Findings showed that VA providers do a better job of testing for and ...
  
  Date: March 1, 2017

» View more Publication Briefs

» View more Studies

• Management Briefs eBrief-no67 - Assessment of Alternative Treatment Strategies for Chronic Genotype 1 Hepatitis C
  ...Treatment Strategies for Chronic Genotype 1 Hepatitis C: A Systematic Review Chronic genotype 1 (GT1) Hepatitis C (HCV) infections have been historically...
  
  
• Assessment of Alternative Treatment Strategies for Chronic Genotype 1 Hepatitis C
  ...C Assessment of Alternative Treatment Strategies for Chronic Genotype 1 Hepatitis C Subscribe to the ESP Report RSS feed Principal Investigator:...
  
  
• FORUM, Spring 2017: Implementation Science
  ...to Table of Contents Research Highlight Strategies to Increase Hepatitis C Treatment Starts Rachel Gonzalez, MPH, National Hepatitis C Resource...
  
  
• Management Briefs eBrief-no81
  ...system, there has been a marked increase in the prevalence of cirrhosis from chronic hepatitis C infection with a corresponding increase in the...
  
  
• Management Briefs eBrief-no81 - Screening for Hepatocellular Cancer in Chronic Liver Disease
  ...there has been a marked increase in the prevalence of cirrhosis from chronic hepatitis C infection with a corresponding increase in the number...
  
  

» View more Publications

» View more Cyberseminars

Videos

There are currently no videos for this topic.

Podcasts

There are currently no podcasts for this topic.

Other Resources

• Visit the VA’s health information page for Veterans on hepatitis C.
• Learn more about the relationship between substance use disorders and hepatitis C through the “Promoting Value & Access in VA's Substance Use Disorder Services” CREATE
• Learn more about the Quality Enhancement Research Initiative’s Bridging the Care Continuum project focusing on liver disease outreach.